712 North leads the way of personalized mitochondrial medicines for patients with age-related illnesses. We are a nimble, science-focused therapeutics company solving the biggest challenges, including Alzheimer’s and cancer. We enable our people so that they can thrive where others throw in the towel. Our values are passion, integrity, respect and excellence. 

Applied Materials is a world-wide largest Semiconductor and Display equipment manufacturer.

Algen, a venture-backed Illumina Accelerator company, is building a next-generation, functional genomics-based platform for the discovery of novel therapeutics for cancers with high unmet need. We have built a productive and collaborative culture, combining the deep expertise of our partners within the drug discovery ecosystem with our nimble team of forward thinking scientists and strategists.

Ambiq Micro is leading the world in energy-efficient semiconductor design, redefining "ultra-low power" with its unique and proprietary Subthreshold Power-Optimized Technology (SPOT) platform.  Our ultra-low power solutions based on SPOT have become the key enablers for battery-operated hearables, remote controls, wearables, smart cards, wireless sensors, IoT and voice-controlled products.

Arris has developed a new automated mass production manufacturing technology. We have developed precisely aligned composites using a novel high-speed manufacturing process that combines 3D printing and advanced manufacturing technologies.

We are a biotech start-up based in Johnson & Johnson Innovation Center (JLABS), South San Francisco. Since August, 2017, we have been developing proprietary biologics/ antibodies to harness the power of the immune system to treat and cure cancer. We focus on the most powerful biological mechanisms that we believe drive disease pathophysiology. While immune checkpoint blockades such as anti-PD-1 and anti-PD-L1 treatment have demonstrated success in a subset of patients across different cancer indications, we delve deeper to understand and solve the problem of why the majority of patients do not respond to these inhibitors. To this end, we have combined bioinformatics with biological assays to identify novel targets involved in cancer-associated suppressive immune modulation, that can be potentially targeted either alone or in synergy with anti-PD-1 therapy. Over the past year, we have successfully identified several such targets and validated their functions on immune cells. We are currently developing clinically viable therapeutic antibodies against two such novel targets in order to provide effective options for those patients who fail to respond to PD-1/PDL1 blockade, and to treat those who otherwise would not be good candidates for existing therapies.

AbVision, Inc. (AVI) previously the Drug Discovery Group of BioVision Inc., is a privately held biopharmaceutical company headquartered in the San Francisco Bay Area. AVI’s most advanced drug discovery efforts aim to develop pipelines of cancer and infectious disease therapeutics that harness the natural power of the immune system to bring first-in-class and best-in-class drugs to the world.

AstraZeneca plc is a multinational pharmaceutical and biopharmaceutical company with headquarters at Cambridge, UK, and it has R&D in three sites: Cambridge, UK; Gaithersburg, Maryland, USA for work on biopharmaceuticals; and Mölndal in Sweden, for research on traditional chemical drugs. AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. 

Belite Bio™ is a San Diego-based clinical-stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease, and diabetes.

Developed from our RBP4 platform technology, our lead candidate, LBS-008, has completed  Phase I clinical trial for dry age-related macular degeneration and its juvenile form, Stargardt disease. LBS-008 has received Orphan Drug Designation in the US and Europe, as well as Rare Pediatric Disease Designation in the US.

Botrista Technology is a robotics AI company focused on automation solutions for the food services industry with a mission of making healthy craft beverages more accessible and affordable. Founded by former Tesla engineers and based in the Silicon Valley, we are pioneers in innovative robotic design with a distinct focus on the beverage industry.

We offer a drink-as-a-service (DaaS) subscription that includes a “robotic barista” Drink Bot machine to automate the labor-intensive process of making specialty drinks such as fruit teas, milk tea, iced coffees, lemonade blends, mocktails/cocktails, and sparkling sodas, and allows food service providers to enhance brand image and drive incremental revenues from premium drink sales without incurring labor costs. The system is designed to be compact, reliable, and easily installed in multiple locations.  We have more than 20 customers in the Bay Area and NYC as for Q1 2020.

The Botrista Team combines decades of robotics expertise and beverage industry experience to develop end-to-end automation solutions to help beverage retailers address the shifting demands from today’s health-conscious consumer. We leverage state-of-the-art manufacturing techniques and integrate smart software to revolutionize the way fresh beverages are prepared and served.
 

BioLegend develops world-class, cutting-edge antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA.  Our mission is to accelerate research and discovery by providing the highest quality products at an outstanding value, along with superior customer service and technical support. 

DSP Concepts is the leading technology company providing audio signal processing solutions for the world's best products such as GoPro, Tesla, Porsche, and Mercedes Benz.  We solve the world's hardest problems such as filtering out 100 mile per hour wind, voice UI in high noise environments, etc..

Perpetually aiming to stay a step ahead of the competition, DynaFlex offers a myriad of services that includes contract manufacturing and supply chain management for reputable customers throughout the medical device field.

We specialize in the following areas:
Neurovascular Coil Delivery
Heart Valve Repair and Replacement Catheter System
Steerable EP Catheters and Sheaths
Specialty catheters – CTO, Atherectomy, Thrombectomy
Embolic Protection and Filter Devices
Intravascular Imaging Devices
Advanced Endoscopic Steering Devices
Balloon and Self Expanding Stent Delivery Systems – PTCA and PTA

Overview
Emerson Collective is a social change organization that uses a broad range of tools including philanthropy, investing, and policy solutions to create the greatest good for the greatest number of people.  Established and led by Laurene Powell Jobs, we work to create new possibilities for individuals and communities.

Emerson Collective is impatient but optimistic, and bold but pragmatic in its approach. We are seeking colleagues with both the audacity to dream up new ways to improve the world, and the determination to make them a reality.

The Opportunity
Our diverse Health venture team is responsible for investing in mission-driven biotechnology companies that are creating innovative solutions to the world’s biggest health problems. We invest in therapeutics, clinical diagnostics, and other opportunities to improve human health. We focused on early-stage companies that are pioneering especially in the oncology space. 

Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.

InnovArt is a Taiwan and LA based startup integrating Tech/ Design/ Business/ and UX talents together to create innovative products which also compliments the user’s lifestyle, and our ultimate goal is to enhance human connectivity through future mobility.

Kneron, a leading provider of edge AI solutions, was founded in San Diego in 2015 by Albert Liu, a leading expert in ASIC design, EDA, deep learning, image processing, and computer vision algorithms. Kneron has partners and customers around the world, and has provided customized solutions for home appliances, surveillance, and Smartphones to several international companies.

Kneron offers innovative edge AI solutions by moving part of the AI computing power from the cloud to edge devices, which makes it different from traditional cloud-based AI solution providers. Kneron’s edge AI solutions are able to do real-time recognition, inference, and analysis with no need to connect to the cloud. Thus, the solutions are faster, more reliable and more secure, while significantly reducing costs and the cloud burden. Kneron offers AI processors Neural Processing Unit (NPU) and visual recognition software that adopt Reconfigurable Artificial Neural Network technology to enable quick implementation of different AI applications, including the detection and recognition of faces, bodies, gestures, objects and scene.

Currently, Kneron has offices in San Diego, Taipei, Zhuhai, and Shenzhen. Our core team members are all from top world class universities, including UCLA, Beijing Tsinghua, Purdue, Taiwan, and Taiwan Tsinghua. Most of the staff are experts in the fields of artificial intelligence, computer vision, and image processing, and some of them come from prestigious technology companies, such as Samsung, Bell Labs, IBM, Qualcomm and Broadcom.

Kneron announced the completion of series A financing in November, 2017. Alibaba Entrepreneurs Fund and CDIB Capital Group are the lead investors, and Himax Technologies Inc, Qualcomm, Thundersoft, Sequoia Capital (sub fund: Cloudatlas), and CY ZONE are co-investors. Kneron completed its series A1 financing led by Horizons Ventures, a venture capital firm founded by Ka-shing Li, in May 2018.

Whether collaborating on smaller solution-based projects or partnering on enterprise-wide transformations using the AI Acceleration Platform, Landing AI is dedicated to propelling teams to success. Founded by one of the most recognizable names in AI, Dr. Andrew Ng, (founding lead of the Google Brain team, and former Chief Scientist at Baidu), and a world class team, the company is uniquely poised to influence the emerging AI generation, and help generate practical AI value for companies worldwide.

LIGHTEL is an advanced technology company located in Seattle to service the Fiber Optic & Photonics industries worldwide. The new focus is to develop Hi-power (KW) technologies for Fiber Laser applications to serve the Industry 4.0., IMS (Intelligent Manufacturing System) and Defense sectors.

mFluiDx is aiming to develop the ultra-low cost, automated point-of-care DNA diagnostic assay for small clinics. In small clinics, such as primary care out-patient clinics, disease diagnosis is typically done by observing symptoms or using paper-strip antibody tests. However, these methods have poor sensitivity compared to DNA diagnostics.  Highly sensitive molecular DNA tests (PCR) are not often used because of cost and the need to send tests off-site resulting in a slow turnaround time (several days).
mFluiDx is a UC Berkeley spinoff startup developing Gates Foundation funded low-cost microfluidic diagnostic technologies capable of on-site multi-target isothermal DNA detection of infectious diseases with simple operation and ~100X lower cost than PCR setups. We aim to create assays that can be deployed in decentralized settings, are as simple and cheap as paper tests, yet have DNA level sensitivity for onsite diagnosis.
mFluiDx has been selected as one of the top 20 finalists from a global competition of 900 startups at Techcrunch’s Startup Battlefield, it has participated the world’s leading biotech startup accelerator (Indiebio Accelerator). It was selected as top 6 early stage startups among all 10 UC campuses. It ranked top 3% among America’s biotech grant applicants. We look forward to work with trainees that can work with us long term and is excited in joining mFluiDx’s vision for next generation diagnostics. 

More info can be found in this video link (CITRIS Foundry demo day pitch): https://youtu.be/WSEKyGikUKU

NVIDIA's invention of the GPU in 1999 sparked the growth of the PC gaming market, redefined modern computer graphics, and revolutionized parallel computing. More recently, GPU deep learning ignited modern AI — the next era of computing — with the GPU acting as the brain of computers, robots, and self-driving cars that can perceive and understand the world.

Pfizer Inc. is an American multinational pharmaceutical corporation headquartered in New York City, with its research headquarters in Groton, Connecticut. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue

SyneuRx Neuroscience is a global CRO and consultation firm engages in a wide scope of activities related to the biopharmaceutical industry in Asia, US, and EU countries.

Sunbird Software is changing the way data centers are being managed. With a focus on real user scenarios for real customer problems, we help data center operators manage tasks and processes faster and more efficient than ever before, while saving costs and improving availability. 

Taiwania Capital is a venture capital firm that was founded in 2017 by the National Development Fund of the Executive Yuan of Taiwan and private enterprises. Our mission is to establish a partnership with companies worldwide and boost Taiwan’s economic growth. We focus on investing in early-stage companies and have launched two funds during 2017-2018.

Fund I was launched with a fund size of US$ 150 million. The key areas are enterprise software, autonomous systems, AI, IoT, robotics & drones, information security, next-gen semiconductors, sensors, and cloud infrastructure. For each industry sector we approach, our investment targets represent those startups with the greatest inchoate potential.

Fund II was launched with a fund size of US$ 200 million. This fund aims to invest in innovative startups in pharmaceutical product research and development, gene/cell therapy and medical technology. By bridging opportunities in Asia and North America, we aim to bring Taiwan’s companies to the forefront of the biotech industry worldwide.

Taiwania Capital is named after Taiwania cryptomerioides, a unique tree species that took its name from Taiwan in 1906. With heights reaching up to 90 meters, the Taiwania tree is one of the tallest tree species in Asia, and surrounding it is a diverse and vibrant ecosystem. By linking technology and capital, Taiwania Capital aspires to also create a robust ecosystem in Taiwan that is rooted in entrepreneurial innovation.

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Taboola helps people find relevant content online, matching them with news stories, articles, blogs, videos, apps, products and other content they’re likely to want to explore.
How do we know what they’ll like? Using machine-learning algorithms, our technology analyzes hundreds of signals to capture exactly what kind of content is most likely to engage each individual. We do that more than 450 billion times a month for more than one billion unique users.

Since we opened our doors in 2006, we have grown to become the leading discovery platform on the open web, serving a combination of the world’s best brands and the most respected global publishers.

Taboola is headquartered in New York City with local offices in Los Angeles, London, Tel Aviv, New Delhi, Bangkok, São Paulo, Beijing, Shanghai, Istanbul, Seoul, Sydney and Tokyo

Company has been developing mmWave phased-array antenna IC, package, modules, and systems for 5G cellular system and Satellite market.

Uber’s mission is to create opportunity through movement. We started in 2010 to solve a simple problem: how do you get access to a ride at the touch of a button? More than 15 billion trips later, we're building products to get people closer to where they want to be. By changing how people, food, and things move through cities, Uber is a platform that opens up the world to new possibilities.

Vizuro operates as a premier incubator for Explainable AI. We utilize our proprietary technology and managed, data-science-as-a-service platform to empower clients to quickly deploy our standard or bespoke solutions in expedited timeframe, then operate them with self-service and augmented support from us.
Our clientele ranges from medical imaging, life science, semiconductor and manufacturing, pharmaceutical companies, and hospitals.

By designing wearable devices in new ways, Wearifi is seeking to create skin-like wireless devices with all of the performance of the current state of the art at a fraction of the size. Our mission is to devise the next generation of electronic solutions – integrated, invisible when you want them to be, and battery-free – to personal healthcare that promote positive feedback between cognitive science and precision medicine.

Wearifi has partnered with multiple Fortune 500 companies, the Department of Health and Human Services, and leading research hospitals to drive personalized healthcare management with wearable electronic gadgets. The core technology represents not only the outcome of a development effort from the research groups of Prof. John A. Rogers at Northwestern University but continuous interactions with the research/clinical teams to develop engineering solutions that are capable of non-invasively skin health monitoring, motion envelope visualization, haptic feedback for VR/AR and prosthetic applications, in-real time. At Wearifi, you’ll have an opportunity to work in a collaborative environment that leads to academic publications and technology innovations, so together we can engineer the future of smart healthcare.